InMed appoints interim CFO and replaces auditor KPMG with Marcum

InMed Pharmaceuticals Inc.

Jonathan Tegge appointed Interim CFO via Brio; monthly fee $9,750. Effective Dec 12, 2022.
KPMG resigned as auditor (Dec 8, 2022); InMed engaged Marcum LLP as replacement, subject to acceptance.
Annual Meeting Dec 15, 2022; management to recommend Marcum appointment using discretionary proxy.
Options granted: 1,400 fully vested shares to Brio; 1,400 shares vesting monthly over 12 months to Tegge.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jonathan Tegge

Interim Chief Financial Officer

INM · InMed Pharmaceuticals Inc.

Effective: 2022-12-12
Filed: December 13, 2022, 6:59 PM ET

As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Tegge was appointed as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-079487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.